498 A Multi-Centre Proof of Concept Study to Assess Efficacy and Safety of a New Liquid Endoscopic Hemostatic Agent (Seraseal / Fastact ®) in Patients With Active Gastrointestinal Bleeding

      Introduction: Endoscopic treatment of severe gastrointestinal bleeding can be difficult and high technical expertise is required. A simple and effective method of endoscopic hemostasis would have a significant impact on the treatment of active gastrointestinal bleeding. Aim of the study is to assess the efficacy and safety of endoscopic hemostasis with liquid combined activated factors IIa, VIIa, IXa, Xa (SerasealTM/Fastact, Wortham Laboratories, Chattanooga, TN, USA).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gastrointestinal Endoscopy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect